nephritis (GN ). Thus uTF levels are significantly raised
Introduction
also been supported by clinical observations and incubated for 30 min at 37°C. Aliquots of the mixtures were experimental models [14, 20, 22] . It is also possible that then assayed using a uTF functional assay as detailed above. renal macrophages and/or tubular cells become activSeparate wells of rrTF were included to serve as positive ated and secrete increased amount of TF, particularly controls. in malignancy and certain types of inflammatory conditions [1, 2] . The stimulus for, and control of, uTF Relipidation studies. uTF extracted from normal urine was production or inhibition remains to be established.
spiked with a platelet substitute (Diagnostic Reagents Ltd In the present study we investigate the functional Thame, Oxon, UK ) which was used as a source of lipid in properties of uTF, the role of uTF-associated vesicles two ways: and the renal localization of uTF.
(i) Directly (n=6); 20 ml (20 mg/ml fc) of lipid was added directly to the assay components in a total volume of 180 ml, in microtitre plates, and the rate of factor Xa generation was Subjects and methods assayed using the uTF assay. 20 ml of factor X assay buffer and lipid were added to separate duplicate wells and this
Functional properties of urinary tissue factor
served as a control.
(ii) Dialysed overnight (n=6); processed urine samples Urinary tissue factor measurements. One millilitre of urine was were spiked with platelet substitute and the mixture dialysed placed in a 1.5-ml microcentrifuge tube and centrifuged at overnight as described by Carson and Konigsberg [23] . 28 000 r.p.m. (51 000 g) for 90 min in an Heraeus Biofuge 28 Fifteen microlitres of processed urine was mixed with 15 ml of RS centrifuge (Jencons, Leighton Buzzard, UK ) at 4°C. The different lipid concentrations (1.25, 2.5, 5.0, 10.0 and supernatant was then discarded and the pellet obtained from 20 mg/ml fc), in 0.01 M Tris with 0.25% of sodium deoxythe centrifugation process was solubilized in 1 ml of 15 mM cholate. 50 ml of a mixture of 0.5 M Tris-HCl-NaCl, pH 7.6, b-octyl-glucopyranoside (BOG, Sigma Chemical Company, with bovine serum albumin (10 mg/ml fc) was added to the Poole, Dorset, UK ) by vortex mixing. The resulting sample previous reagents. Distilled water was added to a total volume was then placed on a slow mixer (Matburn Blood Cell of 0.5 mls. The mixture was then dialysed overnight at 4°C Suspension Mixer, Matburn Surgical Equipment Ltd, against phosphate buffered saline (PBS). The rate of factor X Portsmouth, UK ) for 30 min at room temperature to ensure activation was assessed the following day using the uTF funccomplete solubilization. tional assay, as described above. The assay was conducted in duplicate, in flat-bottomed, 96-well microtitre plates. Each well contained 20 ml (100 nM, Studies on the effect of recombinant Annexin V on urinary final concentration (fc), of purified factor X, American tissue factor activity. Urine samples were obtained from Diagnostica Inc, Greenwich, CT, USA), 10 ml rVIIa (10 nM normal volunteers (n=4) processed and incubated with fc, Novo Nordisk, Denmark), 20 ml Spectrozyme Xa (0.5 mM different concentrations of recombinant Annexin V, 100, 200, fc, American Diagnostica Inc, Greenwich, CT, USA), 20 ml 300, 400, 500 and 1000 nM (kindly donated by Dr De Groot, of CaCl 2 (10 mM, fc), 20 ml of the processed urine sample, Department of Haematology, University Hospital Utrecht, and 90 ml of factor X assay buffer (Tris-NaCl pH 8.0, The Netherlands). The initial reaction was measured using Diagnostic Stago, Asnieres, France). Blank wells contained the uTF assay and the percentage of inhibition was calculated the above reagents with 20 ml of assay buffer instead of factor by comparison with controls, run in parallel in the absence of X, this is used to deduct the average background from the recombinant Annexin V. test samples. The rate of the reaction at 405 nM was determined in a Biokinetics EL-312e micro-plate reader (Bio Tek Instruments, Inc, Winooski, VT, USA) which was pro-Studies on the effect of protease inhibitors in the urine. Urine grammed to read the absorbance at 30-s intervals over a samples were collected from normal subjects (n=7). Eight period of 35 min. Absorbance values were converted to TF millilitres of each sample were stored at 4°C with basic pan-(ng/ml ) using a calibration curve constructed from serial dilu-creatic trypsin inhibitor (BPTI ) 50 mg/ml (Sigma Chemical tions of recombinant relipidated TF (rrTF, 0.4-83 ng/ml ) Company, Pool, Dorset, UK ), and a further 8 ml were stored prepared according to Carson and Konigsberg [23] in BOG. with aprotonin 100 KIU/ml (Bayer Ltd, Pharmaceutical For maximum accuracy the calibration standards were meas-Business Group, Newbury, UK ). The samples were then ured in each plate. assayed for uTF activity at zero time and then daily for 8 The results (ng/ml ) were corrected for the dilution of the consecutive days. A control urine sample without the inhiburine using the creatinine concentration of the sample. Final itors was run in parallel with the test samples. results were expressed as uTF ng/ml per mg creatinine (uTF (ng/ml )/creatinine (mg/dl )×100).
Physical and structural expression of urinary tissue factor, its lipid co-factor and correlation between
Immunological studies. Urine samples from healthy subjects activity and antigenicity in normal human urine (n=6) were processed as described above and incubated with substances known to inhibit TF activity. These include a murine monoclonal antibody against human TF (15 mg/ml Expression of urinary tissue factor on urinary vesicles. One hundred millilitres of urine was collected from healthy volunfinal concentration, fc, American Diagnostica Inc, Greenwich, CT, USA), a polyclonal goat antibody to human teers (n=2) into two sterile universal containers and centrifuged at 2000 g for 15 min to remove any easily sedimentable TF 10 ml (American Diagnostica Inc, Greenwich, CT, USA), Concanavalin A (Con A, 70 mg/ml fc, Sigma Chemical materials. The supernatants were then transferred equally into two ultracentrifuge tubes and spun at 50 000 g for Company, Poole, Dorset, UK ), phospholipase C (70 mg/ml fc, Sigma Chemical Company, Poole, Dorset, UK ) and a 120 min. The supernatant was then discarded and the preembedded pellet of the first tube was resuspended in 1 ml of polyclonal rabbit anti-factor VII antibody (10 units/ml fc, 0.15 M NaCl and the pre-embedded pellet of the second tube Statistical analysis.
was resuspended in 1 ml of BOG. The pre-embedded techniques are highly sensitive and used for immunolabelling Data were included in a database and analysed by the outer membrane antigens [24] . The first and the second Statgraphics@ statistical software system. Data were normally samples were mixed with 50 mg/ml rabbit polyclonal antibody distributed, and summary statistics were expressed as to human TF (American Diagnostica Inc, Greenwich, CT ) means±SD. Differences between groups were assessed using and incubated for 30 min at 37°C. The samples were then Student's t test. Correlations were determined using simple washed and mixed with 50 mg/ml gold-labelled anti-rabbit regression analysis. antibody (BioCell, Wales, UK ), and incubated for further 30 min at the same temperature. They were then centrifuged at 20 000 g for 30 min, washed twice with 0.15 M NaCl, and Results re-pelleted by a further centrifugation. The supernatants were discarded and the pellets were fixed for 24 h in 3% gluteral-Functional properties of urinary tissue factor dehyde in 0.1 sodium cacodylate buffer pH 7.4. They were embedded in Spurr's resin for transmission electron microscopy (TEM ) using the standard protocol of Glauert [25] . Immunological studies. Both rrTF and uTF were inhibUltrathin sections were then viewed using a Hitachi H7000 ited by the monoclonal antibody to human TF, polyelectron microscope (Hitachi Scientific Instrument, Nissei clonal antibody to human TF, Con A, phospholipase Sangyo Ltd, Japan).
C, and by a polyclonal rabbit anti-factor VII antibody ( Figure 1) .
Expression of phospholipid on urinary vesicles. The sample preparation was similar to that described above. The samples were mixed with 50 ml of Annexin V fluorescein isothiocyan-Relipidation studies. The process of relipidating uTF ate (FITC ) (donated by Dr De Groot) and incubated for directly ( Figure 2a) and by dialysing overnight 30 min at 37°C. They were mixed with 50 ml of mouse-anti- ( Figure 2b) showed that the vesicles associated with FITC (BioCell, Wales, UK ) and incubated for further 30 min uTF provided sufficient lipid for its activity. on uTF activity. Samples that were stored with BPTI appear to have slightly lower levels of uTF than the
Immunolocalization of urinary tissue factor within human kidneys and the distribution of anionic phospholipid
Antibody. Murine monoclonal antibody (American Diagnostica Inc, Greenwich, CT, USA) reacts with and neutralizes purified apoprotein of human TF and neutralizes native human brain and placental thromboplastin (in the form of acetone dried powder), TF on tumour cells and on lipopolysaccharide-stimulated monocytes. At a higher concentration of the monoclonal antibody, rabbit TF is significantly inhibited using this antibody (American Diagnostica Inc).
Phospholipid ligand. Annexin V was isolated from full term human placenta by affinity chromatography (the Annexin V was a gift from Dr De Groot of The Department of Haematology, University Hospital Utrecht, The Netherlands).
Streptavidin-biotin-peroxidase complex technique for paraffin embedded tissue using monoclonal antibodies.
Eleven 6-mm kidney sections from normal areas of nephrectomy specimens were stained for TF antigen and Annexin V by the streptavidin-biotin-peroxidase complex (StABC ) tech- Fig. 1 . Characterization of uTF activity. The bars represent the nique for paraffin embedded tissue using monoclonal anti-mean value for each group. uTF was significantly inhibited with all agents. P<0.001 in all cases (mean, n=6).
bodies, according to Mepham and Britten [26 ] .
Characterization of urinary procoagulant activity 591 control group. However, this reduction in activity was not statistically significant. The aprotinin group gave a similar profile to the control group. Figures 4-6. Figure 4 shows lipid-bound vesicles of about 200-500 nM in diameter. Figure 5 shows the results of incubation of processed urine solubilized in buffer with labelled monoclonal antibody to human TF. The label appears to bind to structures within the urine rather than being randomly distributed. Figure 6 shows the effect of detergents on the lipid bound vesicles associated with the uTF. The label now seems to be distributed throughout. No lipid-bound vesicles can be seen. Figure 7 shows the results of incubation of urine preparations with labelled Annexin FITC. The label appears to bind to particles similar to those described above.
Physical and structural expression of urinary tissue factor, its lipid co-factor and correlation between activity and antigenicity in normal human urine Expression of urinary tissue factor on the urinary vesicles. Results are shown in

Expression of phospholipids on urinary vesicles.
Correlation between urinary tissue factor measured as activity and antigen. There was no significant correlation between uTF activity and antigen (r=0.10; P>0.05). Immunolocalization of urinary tissue factor within 
phospholipid
There was no staining of any segment of the nephron in the negative controls with bovine serum albumin, when the primary antibody or the phospholipid ligand were omitted or when the primary TF antibody was pre-adsorbed with excess TF antigen prior to its application (Figure 8a ). In the positive controls the cytoplasm of both distal and proximal tubules but not the glomeruli were positive for TF antigen (Figure 8b ). Sections stained for Annexin V showed comparable staining to that of uTF antigen.
Discussion
The inhibition of uTF activity by agents such as specific anti-human TF antibodies and Con A has been previously reported [1,2,27]. In order to confirm and extend these findings, and to show that the activity being previously measured was TF, agents known to inhibit TF were applied to our assay; monoclonal or polyclonal antibodies to human TF, Con A (a lectin that binds to the saccharide groups of TF (a-methyl mannopyranoside) and prevents its activity) [28] and phospholipase C (which inactivates TF by cleaving associated phospholipid) [29] . uTF activity was markedly inhibited by all these agents. In addition, TF is factor VII-dependent [30, 31] and the activity in our assay was also blocked by a polyclonal rabbit anti-against phospholipid overnight. These studies revealed that the vesicles associated with the uTF provide factor VII antibody. Characterization of the urinary procoagulant activity (PCA) confirms that urinary enough lipid for its activation. They further suggested that no free TF was present in processed urine samples. PCA is derived from TF and lends additional support for the presence of TF-lipid provided by the phospho-The addition of extraneous phospholipid to the uTF assay is therefore not required. lipase C experiments.
Generally, TF must be integrated into phospholipid The action of inhibitors in the urine that might interfere with the uTF activity has previously been for its coagulant activity [32, 33] . uTF has been reported to be associated with membrane vesicles suggested [4] and the degradation of urinary proteins may occur due to the action of proteolytic enzymes [7, 8, 34] . Whether these vesicles provide sufficient lipid for full generation of uTF activity had not been [35, 36 ] . One study has assessed the effect of urinary excretory inhibitors on urinary PCA in patients with previously investigated to our knowledge. In the present studies we attempted to resolve this issue by renal insufficiency and found no association [22] . uTF was reasonably stable at different temperatures which relipidating the uTF both directly and by dialysing partially excludes the possible effect of inhibitors. ticles bind to Con A [34]. However, Con A binding only suggests TF involvement, especially in a complex Indeed, storing the urine samples with both BPTI and aprotinin had no significant effect on the uTF activity. medium such as urine. More direct proof that the vesicles contain TF was established by the labelling of Previous reports provided evidence that urinary PCA is found in subcellular particles [7, 34, 37] which can be their surface by a monoclonal antibody to human TF.
Electron micrographs showed gold-labelled TF on the sedimented following ultracentrifugation [8, 34] . These results have been confirmed by our study. These par-surface of these particles. A few membrane-bound vesicles did not have attached gold particles, suggesting micrographs, yet the gold-labelled TF can still be visualized dispersed throughout the plate. This suggest that not all TF is in a de-encrypted form. In addition, some of these vesicles may have fragmented, under the that the detergent has effectively solubilized the vesicles bearing TF, rendering them a homogeneous suspeninfluence of ultracentrifugation, into smaller particles, which also attract anti-TF. Interestingly, when the sion. Indeed, the recovery in uTF activity after pelleting and solubilizing the pellets is sixfold greater than that urinary pellets containing TF were treated with the detergent BOG, no vesicles were seen in the electron obtained from a raw urine sample (result not shown).
